A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Mark H. Kirschbaum, Paul Frankel, Timothy W. Synold, Zhiliang Xie, Yun Yen, Leslie Popplewell, Robert Chen, Omar Aljitawi, Joseph M. Tuscano, Kenneth K. Chan, Edward M. Newman

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study'. Together they form a unique fingerprint.

Medicine & Life Sciences